AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 151 min read$INM

ADAR1 Capital Management, LLC (Schneeberger Daniel) purchased $13K of INM (indirect holdings)

ADAR1 Capital Management, LLC purchased 9,569 indirectly-held shares of InMed Pharmaceuticals Inc. (INM) at an average of $1.33 ($1.32–$1.33) across 3 trades over 2026-10-13 to 2026-10-15. Filed jointly with Schneeberger Daniel (10% owner).

Original reporting
SEC EDGAR · ADAR1 Capital Management, LLC, Schneeberger Daniel
Published Oct 15, 2026, 8:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$INM
Neutral
low confidence
Mentioned
$INM
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INMNeutralLow
01

Why it matters

Limited impact due to small transaction size; likely no immediate price move.

02

Market read

Minor insider transaction with low trading relevance.

03

What to watch

The purchase is indirect and may reflect broader fund rebalancing rather than company-specific confidence.

Relevance 3/10Novelty 3/10Timing: filed today

Background

Form 4 filing discloses a minor insider purchase by a capital management firm.

Company-level read

Ticker impact

$INMNeutralLow confidence
Context

ADAR1 Capital Management bought 9,569 shares of InMed Pharmaceuticals at $1.33 per share, total $12.7K, increasing its stake to 955,493 shares.

Expected impact

modest upward pressure as market prices in insider buying

Evidence & confidence

Purchase amount is under $15K and represents a tiny fraction of float; unlikely to move price materially.

Market effects

Sector

None significant for biotech sector

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider buying could be a routine portfolio adjustment, not a bullish signal.

Key entities

  • Company
    InMed Pharmaceuticals Inc.

    Biopharmaceutical company listed on NASDAQ under ticker INM.

  • Investor
    ADAR1 Capital Management, LLC

    Investment manager that filed the Form 4 purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

INM insider trading history →

Related articles

OCT 27
$INMMed

InMed Pharmaceuticals: InMed Announces CVR Distribution Record Date in Connection with Proposed Merger

InMed Pharmaceuticals (NASDAQ: INM) set November 5, 2026, as the record date for distributing contingent value rights (CVRs) to shareholders, pending approval of the merger with Mentari Therapeutics and shareholder approval of the Return of Capital Proposal at the November 4, 2026, meeting. The CVRs will be issued under a CVR Agreement, with each shareholder receiving one CVR per common share held as of the record date, but no CVRs will be issued for shares from stock options.

finanznachrichten.de1 min
SEP 18
$INMMed

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Stockholders’ Equity Compliance

InMed Pharmaceuticals Inc. (INM) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Nasdaq: INM c/o Norton Rose Fulbright Canada LLP Suite 1800-510 West Georgia St. Vancouver, BC, Canada V6B 0M3 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Stockholders’ Equi

SEC EDGAR 8-K2 min
SEP 9
$INMMed

InMed Pharmaceuticals: InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update

InMed Pharmaceuticals (INM) reported a net loss of $12.9M for FY2026, up from $8.2M in FY2025. The company is pursuing a merger with Mentari Therapeutics, expected to close by year-end, with Mentari raising $490M in pre-closing financing. InMed's legacy programs, including INM-901, INM-089, and INM-755, are being pursued for strategic opportunities. The company had $2.2M in cash as of June 30, 2026.

finanznachrichten.de2 min
JUL 22
$INMMed

InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline - InMed Pharmaceutica

Mentari Therapeutics raised an additional $200 million via a private placement ahead of its planned merger with InMed Pharmaceuticals (NASDAQ:INM). The deal also closes alongside a previously announced $290 million private placement. Funds extend Mentari’s cash runway into 2029 to support Phase 2a readouts for PACAP-targeted programs, including MT-002. Post-merger, the company will trade on Nasdaq under a new ticker.

benzinga.com4 min
JUL 6
$INMMed

InMed Pharmaceuticals: InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4

InMed Pharmaceuticals (NASDAQ: INM) said it amended a previously announced all-stock merger agreement with privately held Mentari Therapeutics and its merger subsidiaries. InMed filed a preliminary Form S-4 with the SEC for the deal. The boards approved; closing is expected in Q4 2026, pending shareholder approvals and S-4 effectiveness.

finanznachrichten.de3 min